What is William Blair's Forecast for IDXX Q1 Earnings?

Key Points

• William Blair forecasts IDEXX Laboratories to report earnings per share (EPS) of $3.31 for Q1 2026, with full-year estimates at $11.93 EPS.
• Several analysts have set target prices for IDEXX stock, with BTIG Research raising its target to $785.00 and UBS initiating coverage with a target of $720.00.
• IDEXX Laboratories recently experienced insider selling, including a 25.99% decrease in stock ownership by CEO Jonathan Mazelsky after selling nearly $18.5 million worth of shares.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - William Blair issued their Q1 2026 earnings per share (EPS) estimates for IDEXX Laboratories in a research report issued to clients and investors on Tuesday, October 21st. William Blair analyst R. Daniels expects that the company will post earnings per share of $3.31 for the quarter. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share. William Blair also issued estimates for IDEXX Laboratories' Q2 2026 earnings at $3.87 EPS, Q3 2026 earnings at $3.58 EPS and Q4 2026 earnings at $3.32 EPS.

Several other research firms have also issued reports on IDXX. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 4th. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. UBS Group initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, October 1st. They set a "neutral" rating and a $720.00 target price on the stock. Weiss Ratings reissued a "buy (b-)" rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Finally, Leerink Partners increased their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average target price of $656.50.

IDEXX Laboratories Trading Up 0.8%

IDXX stock opened at $638.60 on Friday. The company's 50-day simple moving average is $638.60 and its 200-day simple moving average is $555.86. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories has a 52-week low of $356.14 and a 52-week high of $688.12. The firm has a market cap of $51.09 billion, a P/E ratio of 53.17, a PEG ratio of 4.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the company earned $2.44 earnings per share. IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IDXX. MorganRosel Wealth Management LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at about $26,000. Opal Wealth Advisors LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $30,000. Armstrong Advisory Group Inc. raised its holdings in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after acquiring an additional 30 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 2,187 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company's stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the completion of the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 in the last three months. 0.98% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.